Pharmaceuticals

Generic Central Nervous System Drugs Market Growth Opportunities: Insights from 2025–2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Generic Central Nervous System Drugs Market Expected To Expand Between 2025 And 2029?

The generic central nervous system drugs market has experienced substantial growth in recent years. It is projected to expand from $88.43 billion in 2024 to $93.53 billion in 2025, displaying a compound annual growth rate (CAGR) of 5.8%. This historical growth can be attributed to an increasing number of surgeries, strong expansion in emerging markets, a rise in pharmaceutical R&D, the geriatric population, and increased healthcare expenditure.

The market size for generic central nervous system drugs is projected to experience substantial expansion over the next few years. It is expected to reach $123.41 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the forecast period is largely driven by increasing government initiatives aimed at mental health awareness, a rise in healthcare spending, an expanding elderly population, and a robust pipeline of new drugs. Key trends foreseen in this period involve investments in wearable technology, the utilization of biomarkers in CNS development, the modification of existing medications, continued investment in the drug pipeline, employing 3D printing for drug manufacturing, and a concentrated effort on forming collaborations with research institutions and established companies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9315&type=smp

What Are The Main Drivers Boosting The Generic Central Nervous System Drugs Industry’s Expansion?

The increasing prevalence of mental health disorders is projected to stimulate the growth of the generic central nervous system (CNS) drug market moving forward. A mental health disorder is characterized by a significant clinical disruption in an individual’s cognition, emotional regulation, or behavior, typically linked to distress or functional impairment in critical domains. Generic central nervous system (CNS) drugs are vital in managing mental health disorders by offering affordable and accessible treatment options. For instance, in November 2022, information from the Health and Social Care Information Centre, a UK-based federal body that supplies content, data, and computer systems for experts, physicians, and controllers in the social and healthcare sectors, indicated that the proportion of 17- to 19-year-olds with a suspected mental disorder rose from 17.4% in 2021 to 25.7% in 2022. Therefore, the escalating incidence of mental health disorders is a key driver for the generic central nervous system (CNS) drug market.

What Are The Major Segment Categories Driving The Generic Central Nervous System Drugs Market Growth?

The generic central nervous system drugs market covered in this report is segmented –

1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types

2) By Drug Classification: Branded Drugs, Generic Drugs

3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer

4) By Route Of Administration: Oral, Intravenous, Intranasal Or Inhalation, Other Route Of Administrations

5) By Mode Of Purchase: Over-The-counter drugs, Prescription-Based Drugs

6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Multiple Sclerosis (MS): Interferons, Glatiramer Acetate, Sphingosine-1 Phosphate Receptor Modulators, Monoclonal Antibodies

2) By Anti-Psychotic: Atypical Antipsychotics, Typical Antipsychotics

3) By Analgesics: Non-Opioid Analgesics, Opioid Analgesics, Combination Analgesics

4) By Anti-Parkinson Drugs: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

5) By Anesthetics: General Anesthetics, Local Anesthetics

6) By Anti-Epileptics: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Mechanisms

7) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

8) By Other Types: Cognitive Enhancers, Anxiolytics, Sleep Aids

How Are Emerging Market Trends Shaping The Generic Central Nervous System Drugs Industry Landscape?

Leading firms within the generic central nervous system drugs market are prioritizing the creation of biosimilars targeting central nervous system (CNS) conditions. A growing pattern involves the creation and authorization of biosimilars for specific biologic medications employed in CNS disorders, presenting more economical options compared to their branded counterparts. As an illustration, during October 2023, Sandoz, a pharmaceutical company based in Switzerland, introduced natalizumab-sztn, which is the inaugural biosimilar designed for treating recurrent types of multiple sclerosis (MS). This encompasses clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. MS stands as an autoimmune condition impacting the central nervous system, characterized by its chronic and progressive nature. Most individuals afflicted by the disease experience cycles of remission and relapse, which adversely affects their standard of living. The therapy will not be suitable for patients suffering from progressive multifocal leukoencephalopathy (PML) or those with a history of PML.

Who Are The Top Performing Companies In The Generic Central Nervous System Drugs Market In Recent Years?

Major companies operating in the generic central nervous system drugs market include Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report

Which Regional Markets Are Contributing Most To The Generic Central Nervous System Drugs Industry Expansion?

North America was the largest region in the generic central nervous system drugs market in 2024. The regions covered in the generic central nervous system drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Generic Central Nervous System Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9315&type=smp

Browse Through More Reports Similar to the Global Generic Central Nervous System Drugs Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795